Dystonia: An update on phenomenology, classification, pathogenesis and treatment

Current Opinion in Neurology

Volumn 27, Issue 4, 2014, Pages 468-476

  Balint, Bettina ^a,b   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

approach; classification; dystonia; genetics; phenotype

Indexed keywords

BOTULINUM TOXIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALS2 PROTEIN, HUMAN; ANOCTAMIN 3, HUMAN; ATP1A3 PROTEIN, HUMAN; CHLORIDE CHANNEL; CIZ1 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE EXCHANGE FACTOR; NUCLEAR PROTEIN; OLFACTORY G PROTEIN SUBUNIT ALPHA OLF;

ALS2 GENE; ANOCTAMIN 3 GENE; BODY DISTRIBUTION; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; CIP1 INTERACTING ZINC FINGER 1 GENE; COMBINED DYSTONIA; CONSENSUS; DEAFNESS DYSTONIA SYNDROME; DISEASE CLASSIFICATION; DOPA RESPONSIVE DYSTONIA; DYSTONIA; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; GLOBUS PALLIDUS; GNAL GENE; HUMAN; MISSENSE MUTATION; MYOCLONUS DYSTONIA; NEUROIMAGING; NOMENCLATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARKINSONISM; PATHOGENESIS; PERINATAL ASPHYXIA; PHENOMENOLOGY; REVIEW; RISK FACTOR; SPASTICITY; TREATMENT RESPONSE; TREMOR; TUBB4A GENE; VAGINAL DELIVERY; CLASSIFICATION; GENETICS; MUTATION; PATHOPHYSIOLOGY;

CHLORIDE CHANNELS; DYSTONIA; GTP-BINDING PROTEIN ALPHA SUBUNITS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MUTATION; NUCLEAR PROTEINS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84904071150     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000114     Document Type: Review

References (76)

1. Oppenheim H. About a rare spasm disease of childhood and young age (Dysbasia lordotica progressiva, dystonia musculorum deformans). Neurologische Centralblatt 1911; 30:1090-1107.
2. Charlesworth G, Bhatia KP. Primary and secondary dystonic syndromes: an update. Curr Opin Neurol 2013; 26:406-412.
3. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863-873.
4. Fung VS, Jinnah HA, Bhatia K, Vidailhet M. Assessment of patients with isolated or combined dystonia: an update on dystonia syndromes. Mov Disord 2013; 28:889-898.
5. Fahn S. Classification of movement disorders. Mov Disord 2011; 26:947-957.
6. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18:5-18.
7. Moghimi N, Jabbari B, Szekely AM. Primary dystonias and genetic disorders with dystonia as clinical feature of the disease. Eur J Paediatr Neurol 2014; 18:79-105.
8. Charlesworth G, Plagnol V, Holmström KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet 2012; 91:1041-1050.
9. Stamelou M, Charlesworth G, Cordivari C, et al. The phenotypic spectrum of DYT24 due to ANO3 mutations. Mov Disord 2014. doi: 10.1002/mds.25802.
10. Zech M, Gross N, Jochim A, et al. Rare sequence variants in ANO3 and GNAL in a primary torsion dystonia series and controls. Mov Disord 2014; 29:143-147.
11. Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2012; 45:88-92.
12. Vemula SR, Puschmann A, Xiao J, et al. Role of G((olf) in familial and sporadic adult-onset primary dystonia. Hum Mol Genet 2013; 22:2510-2519.
13. Dufke C, Sturm M, Schroeder C, et al. Screening of mutations in GNAL in sporadic dystonia patients. Mov Disord 2014. doi: 10.1002/mds.25794.
14. Kumar KR, Lohmann K, Masuho I, et al. Mutations in GNAL: a novel cause of craniocervical dystonia. JAMA Neurol 2014; 71:490-494.
15. Charlesworth G, Bhatia KP, Wood NW. No pathogenic GNAL mutations in 192 sporadic and familial cases of cervical dystonia. Mov Disord 2014; 29:154-155.
16. Ma L, Chen R, Wang L, et al. No mutations in CIZ1 in twelve adult-onset primary cervical dystonia families. Mov Disord 2013; 28:1899-1901.
17. Saunders-Pullman R, Fuchs T, San Luciano M, et al. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord 2014; 29:812-818.
18. Belluscio L, Gold GH, Nemes A, Axel R. Mice deficient in G(olf) are anosmic. Neuron 1998; 20:69-81.
19. Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol 2012; 71:458-469.
20. Hersheson J, Mencacci NE, Davis M, et al. Mutations in the autoregulatory domain of (-tubulin 4a cause hereditary dystonia. Ann Neurol 2013; 73:546-553: doi:10.1002/ana.23832.
21. Lohmann K, Wilcox RA, Winkler S, et al. Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol 2013; 73:537-545. doi:10.1002/ana.23829.
22. Vemula SR, Xiao J, Bastian RW, et al. Pathogenic variants in TUBB4A are not found in primary dystonia. Neurology 2014; 82:1227-1230.
23. Simons C, Wolf NI, McNeil N, et al. A de novo mutation in the b-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet 2013; 92:767-773.
24. Wilcox RA, Winkler S, Lohmann K, Klein C. Whispering dysphonia in an Australian family (DYT4): a clinical and genetic reappraisal. Mov Disord 2011; 26:2404-2408.
25. Blumkin L, Halevy A, Ben-Ami-Raichman D, et al. Expansion of the spectrum of TUBB4A-related disorders: a new phenotype associated with a novel mutation in the TUBB4A gene. Neurogenetics 2014; 15:4107-4113.
26. Obeso JA, Rothwell JC, Lang AE, Marsden CD. Myoclonic dystonia. Neurology 1983; 33:825-830.
27. Quinn NP, Rothwell JC, Thompson PD, Marsden CD. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol 1988; 50:391-401.
28. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001; 29:66-69.
29. Spatola M, Wider C. Overview of primary monogenic dystonia. Parkinsonism Relat Disord 2012; 18 (Suppl 1):S158-S161.
30. Carecchio M, Magliozzi M, Copetti M, et al. Defining the epsilon-sarcoglycan (SGCE) gene phenotypic signature in myoclonus-dystonia: a reappraisal of genetic testing criteria. Mov Disord 2013; 28:787-794.
31. Grimes DA, Han F, Lang AE, et al. A novel locus for inherited myoclonusdystonia on 18p11. Neurology 2002; 59:1183-1186.
32. Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133 (Pt 6):1810-1822.
33. Stamelou M, Mencacci NE, Cordivari C, et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 2012; 79:435-441.
34. Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet 2002; 11:971-979.
35. Armstrong MJ, Shah BB, Chen R, et al. Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. Mov Disord 2011; 26:2296-2297.
36. Gras D, Jonard L, Roze E, et al. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 2012; 83:956-962.
37. Schneider SA, Mohire MD, Trender-Gerhard I, et al. Familial dopa-responsive cervical dystonia. Neurology 2006; 66:599-601.
38. Charlesworth G, Mohire MD, Schneider SA, et al. Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology 2013; 81: 1148-1151.
39. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012; 366:636-646.
40. Baschieri F, Batla A, Erro R, et al. Paroxysmal exercise-induced dystonia due to GLUT1 mutation can be responsive to levodopa: a case report. J Neurol 2014; 261:615-616.
41. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995; 38:571-579.
42. Kojovic M, Pareé s I, Lampreia T, et al. The syndrome of deafness-dystonia: clinical and genetic heterogeneity. Mov Disord 2013; 28:795-803.
43. Sheerin UM, Schneider SA, Carr L, et al. ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia. Neurology 2014; 82: 1065-1067.
44. Kurian MA, Zhen J, Cheng SY, et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 2009; 119:1595-1603.
45. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 2014; 137 (Pt 4): 1107-1119.
46. Ozelius LJ. Clinical spectrum of disease associated with ATP1A3 mutations. Lancet Neurol 2012; 11:741-743.
47. Rosewich H, Ohlenbusch A, Huppke P, et al. The expanding clinical and genetic spectrum of ATP1A3-related disorders. Neurology 2014; 82:945-955.
48. Brashear A, Mink JW, Hill DF, et al. ATP1A3 mutations in infants: a new rapidonset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol 2012; 54:1065-1067.
49. Roubergue A, Roze E, Vuillaumier-Barrot S, et al. The multiple faces of the ATP1A3-related dystonic movement disorder. Mov Disord 2013; 28:1457-1459.
50. Cook JF, Hill DF, Snively BM, et al. Cognitive impairment in rapid-onset dystonia-parkinsonism. Mov Disord 2014; 29:344-350.
51. Brashear A, Cook JF, Hill DF, et al. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology 2012; 79:1168-1173.
52. Barbano RL, Hill DF, Snively BM, et al. New triggers and nonmotor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism Relat Disord 2012; 18:737-741.
53. Ulate-Campos A, Fons C, Artuch R, et al. Alternating hemiplegia of childhood with a de novo mutation in ATP1A3 and changes in SLC2A1 responsive to a ketogenic diet. Pediatr Neurol 2013; 50:377-379. [Epub ahead of print]
54. Roubergue A, Philibert B, Gautier A, et al. Excellent response to a ketogenic diet in a patient with alternating hemiplegia of childhood. JIMD Rep 2014. [Epub ahead of print]
55. Novy J, McWilliams E, Sisodiya SM. Asystole in alternating hemiplegia with de novo ATP1A3 mutation. Eur J Med Genet 2014; 57:37-39.
56. Demos MK, van Karnebeek CD, Ross CJ, et al. A novel recurrent mutation in ATP1A3 causes CAPOS syndrome. Orphanet J Rare Dis 2014; 9:15. doi: 10.1186/1750-1172-9-15.
57. Sasaki M, Ishii A, Saito Y, et al. Genotype-phenotype correlations in alternating hemiplegia of childhood. Neurology 2014; 82:482-490.
58. Bøttger P, Tracz Z, Heuck A, et al. Distribution of Na/K-ATPase alpha 3 isoform, a sodium-potassium P-type pump associated with rapid-onset of dystonia parkinsonism (RDP) in the adult mouse brain. J Comp Neurol 2011; 519:376-404.
59. Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset Dystonia-Parkinsonism. Nat Neurosci 2011; 14:357-365.
60. Lohmann K, Schmidt A, Schillert A, et al. Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013. doi: 10.1002/mds.25791. [Epub ahead of print]
61. Mok KY, Schneider SA, Trabzuni D, et al. Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. Mov Disord 2014; 29:245-251.
62. Martino D, Gajos A, Gallo V, et al. Extragenetic factors and clinical penetrance of DYT1 dystonia: an exploratory study. J Neurol 2013; 260:1081-1086.
63. Gavarini S, Vayssiè re N, Delort P, et al. Stereotactic MRI in DYT1 dystonia: focal signal abnormalities in the basal ganglia do not contraindicate deep brain stimulation. Stereotact Funct Neurosurg 2008; 86:245-252.
64. Jankovic J. Medical treatment of dystonia. Mov Disord 2013; 28:1001-1012.
65. Bronte-Stewart H, Taira T, Valldeoriola F, et al. Inclusion and exclusion criteria for DBS in dystonia. Mov Disord 2011; 26 (Suppl 1):S5-S16.
66. Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012; 11:1029-1038.
67. Yamada K, Hamasaki T, Hasegawa Y, Kuratsu J. Long disease duration interferes with therapeutic effect of globus pallidus internus pallidal stimulation in primary cervical dystonia. Neuromodulation 2013; 16:219-225.
68. Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013; 136 (Pt 3):761-769.
69. Andrews C, Aviles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81:1383-1389.
70. Markun LC, Starr PA, Air EL, et al. Shorter disease duration correlates with improved long-term deep brain stimulation outcomes in young-onset DYT1 dystonia. Neurosurgery 2012; 71:325-330.
71. Zittel S, Moll CK, Brüggemann N, et al. Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families. Mov Disord 2010; 25:2405-2412.
72. Groen JL, Ritz K, Contarino MF, et al. DYT6 dystonia: mutation screening, phenotype, and response to deep brain stimulation. Mov Disord 2010; 25:2420-2427.
73. Panov F, Tagliati M, Ozelius LJ, et al. Pallidal deep brain stimulation for DYT6 dystonia. J Neurol Neurosurg Psychiatry 2012; 83:182-187.
74. Rughani AI, Lozano AM. Surgical treatment of myoclonus dystonia syndrome. Mov Disord 2013; 28:282-287.
75. Mentzel CL, Tenback DE, Tijssen MA, et al. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry 2012; 73:1434-1438.
76. Moro E, Gross RE, Krauss JK. What's new in surgical treatment for dystonia? Mov Disord 2013; 28:1013-1020.